- Analgesic
- Artificial Digestive Enzyme
- Protein Supplements
- Steroids
- Antibiotics
- Others
Chronic Pancreatitis Market was valued at USD 8.2 billion in 2022 and is poised to grow at a CAGR of 5.7% over 2023-2029. Chronic Pancreatitis is a long-standing inflammation of the pancreas that alters the organ’s normal structure and functions, has symptoms such as upper abdominal pain, nausea and vomiting, steatorrhea, weight loss, and diabetes type I, and the causes of the disease include alcoholism, autoimmune disorders, intraductal obstruction, idiopathic pancreatitis, tumors, ischemia, and others. According to the Global Burden of Disease (2017), the global estimation of incidence and mortality was 9.62 cases per 1,00,000 person-years and 0.09 deaths per 1,00,000 person-years, respectively for chronic pancreatitis. An increase in consumption of alcohol and a rise in unhealthy lifestyles will act as the growth drivers for the market. However, the high cost of treatment will have a restraining impact on the chronic pancreatitis market growth. Technological advancements and increasing healthcare expenditure are the opportunities for market expansion.
Chronic Pancreatitis Market Key Developments:
- In Dec 2021, Kangen Pharmaceuticals completed a phase-I/II trial in pancreatitis in the USA, for NI-03.
- In July 2023, First Wave BioPharma announced its intention to submit BLA for Adrulipase alfa to the US FDA for exocrine pancreatic insufficiency.
Chronic Pancreatitis Market Summary
Study Period
2023-29
Base Year
2022
CAGR
5.7%
Largest Market
North America
Fastest Growing Market
North America
Chronic Pancreatitis Market Dynamics
The increase in government initiatives and investments in R&D activities by the pharmaceutical companies for drug development are the major factors driving the market growth. For instance, in Aug 2020, CT Pharmaceutical Solutions held a meeting to add chronic pancreatitis condition to the Medical Marijuana Program for adults and for patients under 18 “whose pain is recalcitrant to standard medical management”. Thus, the increased awareness, research and development for chronic disorders will lead to the growth of the market within the forecast period, whereas, lack of skilled professionals with no proper line of treatment for the disease in the market could hamper the market growth.
North-America Got Significant Share of
Chronic Pancreatitis Market Regional Analysis
The chronic Pancreatitis market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the World Health Organization, around 4,95,773 patients were diagnosed with pancreatic cancer around the globe in 2020. As per an article published by the National Library of Medicine, chronic alcohol use, one of the common causes of gallstones, accounted for 17% to 25% of cases of the condition globally, in 2022. The North America Chronic Pancreatitis market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems, and increasing alcohol consumption in the United States and Canada. Europe is anticipated to see growth in the chronic pancreatitis market owing to the changing unhealthy lifestyle, and eating habits of the population in countries such as the UK and Germany. The Asia Pacific region is also expected to cover a large market share due to the growing population in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic pancreatitis market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Pancreatitis Market Segmentation
By Treatment
By Causes
- Damaged Pancreatic Duct
- Cancer
- Auto-Immune Disorder
- Cystic Fibrosis
- Gall Stones
- Hereditary
- Others
By Diagnosis
- CT Scan
- Magnetic Resonance Cholangiopancreatography
- Ultrasound Sonography
- Others
By Route of Administration
- Oral
- Parenteral
By End User
- Hospitals
- Homecare
- Others
Frequently Asked Questions
The Chronic Pancreatitis market was valued at USD 8.2 billion in 2022 and is expected to grow at a 5.7% CAGR over the forecast period 2023 – 2029.
Technological advancements and increasing healthcare expenditure are the key opportunities for the Chronic Pancreatitis market.
An increase in consumption of alcohol and a rise in unhealthy lifestyles are the growth drivers in the Chronic Pancreatitis market.
Kangen Pharma, AzurRX BioPharma, Theraly Fibrosis, First Wave BioPharma., Pfizer Inc., Baxter, B Braun, Hoffmann-La Roche Ltd., and Merck & Co., Inc. are a few companies operating in the Chronic Pancreatitis market.
- Kangen Pharma
- AzurRX BioPharma
- Theraly Fibrosis
- First Wave BioPharma.
- Pfizer Inc.
- Baxter
- B Braun
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Sanofi